• Vaccine Name: live TC-83 VEE Vaccine with DHEA
• Target Pathogen: VEE Virus
• Target Disease: Venezuelan equine encephalitis
• Vaccine Ontology ID: VO_0004261
• Type: Live, attenuated vaccine
• Status: Research
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001340
  • Description: DHEA (Sigma Chemical Co., St. Louis, MO, U.S.A.) was dissolved in 50% ethanol. Mice were injected with DHEA (10 mg/Kg), in 0.3 mL, subcutaneously (s.c.), 4 hours before vaccination (Negrette et al., 2001).
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: NMRI-IVIC
• Vaccination Protocol: Mice were immunized intraperitoneally (i.p.) with 0.05 mL of live TC-83 VEE virus suspension, containing 1.7 x 106 PFU/mL, in 0.4% BABS. Virus stock from IVIC was replicated in VERO cell culture and contained 106.78 LD50. DHEA (Sigma Chemical Co., St. Louis, MO, U.S.A.) was dissolved in 50% ethanol. Mice were injected with DHEA (10 mg/Kg), in 0.3 mL, subcutaneously (s.c.), 4 hours before vaccination. Control mice were injected with the diluent (Negrette et al., 2001).
• Immune Response: In mice treated with a single dose of DHEA, a significant increase (p<0.01) of antibody titers (Control = 1:1.680 vs. DHEA treated group = 1:4.320) was detected at week 2 after vaccination with TC-83 virus (Negrette et al., 2001).
• Challenge Protocol: Live VEE virus (10 LD50) was injected in mice treated with DHEA, 21 days after immunization, and 2 to 5 days later they were sacrificed to determine viral titers in serum and brain (Negrette et al., 2001).
• Efficacy: MIce immunized with the TC-83 virus and DHEA had reduced viremia in the blood and brain after challenge (Negrette et al., 2001).